Presentation of Ipsen's advances in neurological diseases at the TOXINS congress

At the TOXINS 2026 congress in Madrid, Ipsen presented 14 papers on various neurological disorders, including post-stroke spasticity, cervical dystonia, and blepharospasm. The EPITOME study revealed that 45.7% of stroke survivors develop spasticity within a year of the event.

This multicenter study of adults after a first stroke aims to facilitate the early detection of spasticity through a specific questionnaire, in order to improve patient management. Despite these results, less than 1% of patients receive treatment with BoNT-A, highlighting a critical gap in care.

Sandra Silvestri, Executive Vice President of Ipsen, reiterated the company's commitment to addressing these gaps in the management of neurological diseases.